Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions
Diabetic Macular Edema (DME)
Interventions
DRUG

UBX1325

Patients will be administered a single 50 μL UBX1325 IVT injection

OTHER

Sham

Sham procedure

Trial Locations (22)

10003

New York Eye and Ear Infirmary, New York

21740

Cumberland Valley Retina Consultants, Hagerstown

29605

Retina Consultants of Carolina, PA, Greenville

33136

Bascom Palmer Eye Institute, Miami

33143

MedEye Associates, Miami

46290

MidWest Eye Institute, Indianapolis

60611

Northwestern Medical Group, Chicago

76092

Retina Center of Texas, Southlake

78503

Valley Retina Institute, P.A., McAllen

80503

Advanced Vision Research Institute, Longmont

85053

Retinal Research Institute, LLC, Phoenix

89502

Sierra Eye Associates, Reno

91436

The Retina Partners, Encino

92354

Loma Linda University, Loma Linda

92647

Salehi Retina Institute Inc., Huntington Beach

93036

California Retina Consultants, Oxnard

93309

California Retina Consultants, Bakersfield

97225

EyeHealth Northwest, Portland

02114

Mass Eye and Ear Institute, Boston

T5H OX5

Alberta Retina Research Corporation, Edmonton

M3C 0G9

Toronto Retina Institute, North York

H1T 2M4

Hopital Maisonneuve-Rosemont, Montreal

All Listed Sponsors
lead

Unity Biotechnology, Inc.

INDUSTRY